Allogene Therapeutics Inc (NASDAQ:ALLO) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 12,830,000 shares, a growth of 9.6% from the December 15th total of 11,710,000 shares. Approximately 26.9% of the shares of the company are sold short. Based on an average trading volume of 537,500 shares, the short-interest ratio is presently 23.9 days.
NASDAQ:ALLO opened at $26.62 on Thursday. The stock has a 50-day simple moving average of $27.34 and a two-hundred day simple moving average of $27.83. Allogene Therapeutics has a 52-week low of $24.60 and a 52-week high of $33.80. The company has a debt-to-equity ratio of 0.06, a current ratio of 15.28 and a quick ratio of 15.28.
Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.04. As a group, equities analysts predict that Allogene Therapeutics will post -1.93 earnings per share for the current year.
ALLO has been the subject of several research analyst reports. ValuEngine raised Allogene Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, December 30th. JPMorgan Chase & Co. reissued a “hold” rating and set a $29.00 price target on shares of Allogene Therapeutics in a report on Wednesday, November 6th. William Blair reissued a “buy” rating on shares of Allogene Therapeutics in a report on Tuesday, November 5th. Canaccord Genuity initiated coverage on Allogene Therapeutics in a report on Monday, November 4th. They set a “buy” rating and a $36.00 price target for the company. Finally, JMP Securities initiated coverage on Allogene Therapeutics in a report on Wednesday, December 18th. They set an “outperform” rating and a $37.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Allogene Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $36.20.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Featured Article: Google Finance Portfolio
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.